MCID: ART140
MIFTS: 51

Arteries, Anomalies of

Categories: Cardiovascular diseases

Aliases & Classifications for Arteries, Anomalies of

MalaCards integrated aliases for Arteries, Anomalies of:

Name: Arteries, Anomalies of 53
Artery Disease 12 14
Arteriopathic Disease 69

Characteristics:

OMIM:

53
Inheritance:
autosomal dominant


HPO:

31
arteries, anomalies of:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 53 108000
Disease Ontology 12 DOID:0050828
MedGen 39 C1876179
SNOMED-CT via HPO 65 263681008 49601007
UMLS 69 C0852949

Summaries for Arteries, Anomalies of

Disease Ontology : 12 A vascular disease that is located in an artery.

MalaCards based summary : Arteries, Anomalies of, also known as artery disease, is related to peripheral artery disease and carotid artery disease, and has symptoms including abnormality of the cardiovascular system An important gene associated with Arteries, Anomalies of is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Vesicle-mediated transport and Lipoprotein metabolism. The drugs Everolimus and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include an artery, and related phenotypes are Decreased free cholesterol and cardiovascular system

Description from OMIM: 108000

Related Diseases for Arteries, Anomalies of

Diseases related to Arteries, Anomalies of via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 499)
# Related Disease Score Top Affiliating Genes
1 peripheral artery disease 34.5 ACE APOB CRP IL6 NOS3
2 carotid artery disease 34.3 ACE APOA1 APOB APOE COG2 CRP
3 renal artery disease 34.2 ACE AGTR1 NOS3 REN
4 peripheral vascular disease 33.5 ACE ALB APOA1 APOB CRP IL6
5 coronary artery anomaly 33.4 ACE AGTR1 APOA1 APOB APOE COG2
6 hyperlipoproteinemia, type iii 33.3 APOA1 APOB APOE COG2 LPA
7 hypercholesterolemia, familial 33.1 APOA1 APOB APOE COG2 CRP INS
8 coronary heart disease 1 33.0 ACE APOA1 APOB APOE COG2 CRP
9 hyperlipidemia, familial combined 32.6 APOA1 APOB APOE
10 prinzmetal's variant angina 32.6 EDN1 NOS3
11 fibromuscular dysplasia 32.6 ACE AGTR1 REN
12 aortic disease 32.5 APOE IL6 REN
13 pulmonary embolism 32.5 ALB CRP PLAT TNNI3
14 tangier disease 32.4 ALB APOA1 APOB APOE LPA
15 heart disease 32.2 ACE AGTR1 ALB APOB APOE CRP
16 cerebrovascular disease 32.1 ACE AGTR1 APOA1 APOB APOE CRP
17 atherosclerosis susceptibility 32.1 ACE APOA1 APOB APOE COG2 CRP
18 arteriosclerosis 32.1 ACE APOA1 APOB APOE COG2 CRP
19 hypercholesterolemia, autosomal dominant, type b 32.0 APOB APOE
20 myocardial infarction 31.8 ACE AGTR1 ALB APOA1 APOB APOE
21 ischemia 31.5 ACE EDN1 NOS3 PLAT TRPV1
22 diabetes mellitus 31.5 ACE ALB CRP IL6 INS
23 intermittent claudication 31.4 ACE ALB CRP IL6
24 stroke, ischemic 31.4 ACE AGTR1 APOB APOE COG2 CRP
25 angina pectoris 31.4 ACE CRP IL6 PLAT
26 limb ischemia 31.2 ACE EDN1 IL6 NOS3 TNNI3
27 acute myocardial infarction 31.1 ACE CRP EDN1 PLAT PLG TNNI3
28 aortic aneurysm, familial abdominal, 1 31.0 ACE APOE CRP IL6
29 aortic valve disease 2 31.0 ACE CRP REN TNNI3
30 aortic atherosclerosis 30.9 ACE APOE LPA
31 systolic heart failure 30.9 ACE CRP IL6
32 carotid stenosis 30.8 ACE APOE CRP
33 coronary stenosis 30.8 ACE ALB APOA1 APOB APOE CRP
34 congestive heart failure 30.8 ACE AGTR1 EDN1 REN
35 periodontitis 30.8 CRP IL6 TLR9
36 cardiogenic shock 30.7 CRP IL6 PLAT
37 apnea, obstructive sleep 30.7 CRP EDN1 IL6 INS REN
38 kidney disease 30.7 ACE AGTR1 ALB APOE EDN1 LPA
39 hypertriglyceridemia, familial 30.7 APOA1 APOB APOE INS
40 chronic kidney failure 30.6 ACE AGTR1 ALB CRP EDN1 IL6
41 ischemic heart disease 30.6 ACE APOA1 APOB APOE CRP IL6
42 vascular disease 30.6 ACE APOA1 APOB APOE CRP EDN1
43 body mass index quantitative trait locus 11 30.6 APOA1 APOB APOE COG2 CRP IL6
44 aortic coarctation 30.6 ACE AGTR1 EDN1 NOS3
45 myocardial stunning 30.6 AGTR1 EDN1 TNNI3
46 microvascular complications of diabetes 5 30.6 ACE AGTR1 ALB INS NOS3
47 mitral valve disease 30.5 ACE AGTR1 NOS3
48 sleep apnea 30.5 ACE APOE CRP EDN1 IL6 INS
49 end stage renal failure 30.5 ACE AGTR1 ALB CRP IL6
50 xanthomatosis 30.5 APOB APOE LPA

Graphical network of the top 20 diseases related to Arteries, Anomalies of:



Diseases related to Arteries, Anomalies of

Symptoms & Phenotypes for Arteries, Anomalies of

Symptoms via clinical synopsis from OMIM:

53
Vascular:
abnormal radial, ulnar, or interosseous artery


Clinical features from OMIM:

108000

Human phenotypes related to Arteries, Anomalies of:

31
# Description HPO Frequency HPO Source Accession
1 abnormality of the cardiovascular system 31 HP:0001626

GenomeRNAi Phenotypes related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 8.92 APOA1 APOB APOE LPA

MGI Mouse Phenotypes related to Arteries, Anomalies of:

43 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.41 APOE CRP EDN1 IL6 INS NOS3
2 homeostasis/metabolism MP:0005376 10.36 COG2 CRP EDN1 IL6 INS NOS3
3 growth/size/body region MP:0005378 10.29 ACE AGTR1 APOB APOE COG2 EDN1
4 cellular MP:0005384 10.26 IL6 INS NOS3 ALB APOA1 APOB
5 immune system MP:0005387 10.22 ACE AGTR1 APOB APOE CRP IL6
6 hematopoietic system MP:0005397 10.2 NOS3 PLAT PLG REN TLR9 ACE
7 endocrine/exocrine gland MP:0005379 10.19 ACE ALB APOA1 APOE EDN1 IL6
8 mortality/aging MP:0010768 10.17 PLAT PLG REN TLR9 ACE AGTR1
9 digestive/alimentary MP:0005381 10.16 EDN1 IL6 INS NOS3 PLAT PLG
10 adipose tissue MP:0005375 10.09 ACE AGTR1 APOE IL6 INS NOS3
11 liver/biliary system MP:0005370 10.07 ACE ALB APOA1 APOB APOE IL6
12 muscle MP:0005369 9.96 APOE EDN1 IL6 INS NOS3 PLAT
13 nervous system MP:0003631 9.9 AGTR1 APOB APOE EDN1 IL6 INS
14 renal/urinary system MP:0005367 9.73 ACE AGTR1 ALB APOE EDN1 IL6
15 reproductive system MP:0005389 9.28 ACE APOB APOE IL6 INS NOS3

Drugs & Therapeutics for Arteries, Anomalies of

Drugs for Arteries, Anomalies of (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 940)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
3
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
4
Clopidogrel Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 120202-66-6, 113665-84-2 60606
5
Ticagrelor Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 274693-27-5 9871419
6
Ticlopidine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55142-85-3 5472
7
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 73963-72-1 2754
8
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 46507594 772
9
Tirofiban Approved Phase 4,Phase 3,Phase 1 144494-65-5 60947
10
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55-56-1 2713 9552079
11
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 79902-63-9 54454
12
Trimetazidine Approved, Investigational Phase 4 5011-34-7
13
Insulin Glargine Approved Phase 4,Phase 3 160337-95-1
14
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 4091 14219
15
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 7440-66-6 32051 23994
16
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
17
Amlodipine Approved Phase 4,Phase 3,Not Applicable 88150-42-9 2162
18
Rivaroxaban Approved Phase 4,Phase 3,Phase 2 366789-02-8
19
Warfarin Approved Phase 4,Phase 3,Not Applicable 81-81-2 54678486 6691
20
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1,Not Applicable 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
21
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
22
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 95635-55-5, 142387-99-3 56959
23
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
24
Chromium Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-47-3 27668
25
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
26
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 122320-73-4 77999
27
Pitavastatin Approved Phase 4,Phase 3,Not Applicable 147511-69-1, 147526-32-7 5282452 6366718
28
Ezetimibe Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 163222-33-1 150311
29
Lovastatin Approved, Investigational Phase 4,Phase 2,Phase 3 75330-75-5 53232
30
Acarbose Approved, Investigational Phase 4,Phase 3,Not Applicable 56180-94-0 441184
31
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128270-60-0 16129704
32
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51384-51-1, 37350-58-6 4171
33
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable
34
Vorapaxar Approved Phase 4,Phase 3,Phase 2 618385-01-6
35
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-61-7 60961
36
Dipyridamole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-32-2 3108
37
Regadenoson Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 313348-27-5 219024
38
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3 73590-58-6 4594
39
Pantoprazole Approved Phase 4,Phase 3,Not Applicable 102625-70-7 4679
40
Dopamine Approved Phase 4,Phase 2,Phase 3,Not Applicable 51-61-6, 62-31-7 681
41
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
42
Coal tar Approved Phase 4,Phase 1,Phase 2 8007-45-2
43
Eptifibatide Approved, Investigational Phase 4,Phase 3,Phase 2 188627-80-7 123610
44
Menthol Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 2216-51-5 16666
45 sodium fluoride Approved Phase 4,Phase 2,Not Applicable 7681-49-4
46
Nicorandil Approved, Investigational Phase 4,Not Applicable 65141-46-0 47528
47
Phenprocoumon Approved, Investigational Phase 4 435-97-2 54680692 9908
48
Esmolol Approved Phase 4,Phase 3,Not Applicable 81147-92-4, 103598-03-4 59768
49
Nicardipine Approved, Investigational Phase 4,Early Phase 1 55985-32-5 4474
50 Trapidil Approved Phase 4 15421-84-8

Interventional clinical trials:

(show top 50) (show all 6165)

# Name Status NCT ID Phase Drugs
1 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
2 Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease Unknown status NCT02514642 Phase 4 low-dose ticagrelor;Clopidogrel
3 A Trial to Evaluate Efficacy of Heart-protecting Musk Pill Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
4 Far Infrared Therapy on Peripheral Artery Disease in Hemodialysis Patients Unknown status NCT01095549 Phase 4
5 Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease Unknown status NCT02174939 Phase 4 Cilostazol;Dummy Placebo
6 Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
7 The Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients Unknown status NCT01633359 Phase 4 Intensive statin;Routine statin
8 Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease Unknown status NCT01373632 Phase 4
9 Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa) Unknown status NCT02030054 Phase 4 Atorvastatin;Rosuvastatin
10 Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
11 The ImPact of Trimetazidine on MicrOcirculation After Stenting for Stable Coronary Artery Disease Unknown status NCT02107144 Phase 4 trimetazidine
12 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4 insulin glargine;metformin
13 Residual Platelet Activity In Advanced Peripheral Artery Disease Unknown status NCT01627431 Phase 4 Acetylsalicylic acid;Clopidogrel
14 Xience/Promus for Long Coronary Lesion Registry Unknown status NCT01147237 Phase 4
15 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
16 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
17 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
18 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
19 Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF) Unknown status NCT02373462 Phase 4 Olmesartan;other anti-hypertensive drug
20 Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity Unknown status NCT01490255 Phase 4 Ranolazine;Amlodipine
21 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT) Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
22 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
23 Efficacy Study of Stenting, Paclitaxel Eluting Balloon or Atherectomy to Treat Peripheral Artery Disease Unknown status NCT00986752 Phase 4
24 BioMime Vs. Xience Randomised Control Clinical Study Unknown status NCT02112981 Phase 4
25 Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease Unknown status NCT01901224 Phase 4 Metformin 1000 mg;Placebo
26 Safety and Effectiveness of the Coronary Momo Stent Unknown status NCT01535625 Phase 4
27 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
28 Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROL Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease Unknown status NCT01653600 Phase 4
29 Assessment of Surface Coverage of Two Types of DES in Diabetes Mellitus and Non- Diabetes Mellitus Unknown status NCT01023919 Phase 4
30 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor Unknown status NCT01869309 Phase 4 Prasugrel;Ticagrelor
31 Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
32 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
33 Multivessel Stenting Versus Staged Revascularization With Zotarolimus-eluting Stent for STEMI Unknown status NCT01781715 Phase 4
34 PharmacOdynamic compaRison of piTavastatin Versus atOrvastatin on Platelet Reactivity Unknown status NCT01648829 Phase 4 Atorvastatin;Pitavastatin
35 SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy Unknown status NCT00403078 Phase 4
36 A Multicenter, Therapeutic Used Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease Unknown status NCT01711333 Phase 4 Pletaal SR capsule
37 Cholesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant Patients Unknown status NCT01807078 Phase 4 Ezetimibe
38 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4 acarbose
39 Ranolazine, Ethnicity and the Metabolic Syndrome Unknown status NCT01304095 Phase 4 Ranolazine
40 Platelets Induced Vasodilation, in Vitro and in Vivo Study Unknown status NCT00152646 Phase 4 placebo, aspirine, clopidogrel
41 Periodontal Therapy in Coronary Artery Patients Unknown status NCT01609725 Phase 4
42 Plasma and Platelet microRNAs in Clopidogrel Low Response Patients Unknown status NCT02447809 Phase 4 Clopidogrel;acetylsalicylic acid (ASA)
43 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4
44 Italian Diffuse/Multivessel Disease ABSORB Prospective Registry: IT-Disappears Unknown status NCT02004730 Phase 4
45 The Effects of Omega 3 and Vitamin E Supplementation on the Serum Antioxidant Enzymes and Gene Expressions of PGC-1a, h TERT, FOXOs and SIRTs in CAD Patients Unknown status NCT02011906 Phase 4
46 A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization Unknown status NCT01157455 Phase 4 Aspirin;Clopidogrel;Heparin or Bivalirudin
47 Diagnostic Performance of Noninvasive Fractional Flow Reserve From Computed Tomography Unknown status NCT01747317 Phase 4
48 Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent Unknown status NCT01233453 Phase 4
49 Graft Patency After FFR-guided Versus Angio-guided CABG (GRAFFITI) Trial Unknown status NCT01810224 Phase 4
50 The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus Unknown status NCT02418884 Phase 4 rosuvastatin

Search NIH Clinical Center for Arteries, Anomalies of

Genetic Tests for Arteries, Anomalies of

Anatomical Context for Arteries, Anomalies of

The Foundational Model of Anatomy Ontology organs/tissues related to Arteries, Anomalies of:

18
An Artery

Publications for Arteries, Anomalies of

Articles related to Arteries, Anomalies of:

(show top 50) (show all 5010)
# Title Authors Year
1
Risk Factors for Carotid Artery Disease and Chronic Kidney Disease: Same or Unique? ( 29405657 )
2018
2
Protecting Life and Limb in Peripheral Artery Disease. ( 29358343 )
2018
3
Peripheral Artery Disease and Continuous Flow Left Ventricle Assist Device: An Engaging Complement Analysis May Help to Guide Treatment. ( 29436002 )
2018
4
Antithrombotic therapy in peripheral artery disease: A review of the EUCLID trial results and current ongoing trials. ( 29355992 )
2018
5
Lipid-lowering treatment in peripheral artery disease. ( 29413998 )
2018
6
Low Plasma Levels of Fibroblast Growth Factor-21 in Patients with Peripheral Artery Disease. ( 29367522 )
2018
7
Accelerated collagen turnover in women with angina pectoris without obstructive coronary artery disease: An iPOWER substudy. ( 29436257 )
2018
8
Diagnostic accuracy of the postexercise ankle-brachial index for detecting peripheral artery disease in suspected claudicants with and without diabetes. ( 29432708 )
2018
9
The Role of Neurosonology in the Diagnosis and Management of Patients with Carotid Artery Disease: A Review. ( 29334161 )
2018
10
Prader-Willi syndrome: a nest for premature coronary artery disease? ( 29437709 )
2018
11
Impact of peripheral artery disease on early and late outcomes of transcatheter aortic valve implantation in patients with severe aortic valve stenosis. ( 29425561 )
2018
12
Peripheral artery disease. ( 29419394 )
2018
13
Abnormal Repolarization Duration during Everyday Emotional Arousal in Long QT Syndrome and Coronary Artery Disease. ( 29309742 )
2018
14
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. ( 29389037 )
2018
15
Race and Socioeconomic Status Independently Affect Risk of Major Amputation in Peripheral Artery Disease. ( 29330260 )
2018
16
Peripheral artery disease is associated with frailty in chronic hemodialysis patients. ( 29402196 )
2018
17
PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease. ( 29412075 )
2018
18
Transcarotid Transcatheter Aortic Valve Replacement as Preferred Alternative Access in a Patient With Bilateral Carotid Artery Disease. ( 29289952 )
2018
19
Peripheral artery disease and transcatheter aortic valve implantation: The tip of the atherosclerotic iceberg. ( 29425563 )
2018
20
Increased Risk of Peripheral Arterial Disease in Patients With Abdominal Aortic Aneurysm: A Retrospective Cohort Study (Version 5). ( 29444589 )
2018
21
Growing evidence for coronary artery disease risk factors in patients with severe hidradenitis suppurativa. ( 29357611 )
2018
22
Time trends in peripheral artery disease incidence, prevalence and secondary preventive therapy: a cohort study in The Health Improvement Network in the UK. ( 29358428 )
2018
23
Could the stress hyperglycemia ratio predict the clinical outcomes of coronary artery disease patients after percutaneous coronary intervention? ( 29407118 )
2018
24
Dual Anticoagulant and Antiplatelet Therapy for Coronary Artery Disease and Peripheral Artery Disease Patients. ( 29449336 )
2018
25
Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy. ( 29408797 )
2018
26
Cost-effectiveness analysis of asymptomatic peripheral artery disease screening with the ABI test. ( 29345540 )
2018
27
Toe-brachial index and exercise test can improve the exploration of peripheral artery disease. ( 29366987 )
2018
28
Improvement of bilateral lower-limb muscle oxygenation by low-density lipoprotein apheresis in a patient with peripheral artery disease undergoing hemodialysis. ( 29422296 )
2018
29
High-Sensitivity Cardiac Troponin I and the Diagnosis of Coronary Artery Disease in Patients With Suspected Angina Pectoris. ( 29444926 )
2018
30
The associatA+on between serum serglycin level and coronary artery disease severity in patients with stable angina pectoris. ( 29313562 )
2018
31
A case report of combined radical pericardiectomy and beating heart coronary artery bypass grafting in a patient with tubercular chronic constrictive pericarditis with coronary artery disease. ( 28994689 )
2017
32
Assessment of IL-18 Serum Level and Its Promoter Polymorphisms in the Saudi Coronary Artery Disease (CAD) Patients. ( 28059484 )
2017
33
Significant association of RNF213 p.R4810K, a moyamoya susceptibility variant, with coronary artery disease. ( 28414759 )
2017
34
Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease. ( 28073668 )
2017
35
Meta-analysis of the association of the CYP2J2 G-50T polymorphism with coronary artery disease. ( 28938665 )
2017
36
Association between STK11 Gene Polymorphisms and Coronary Artery Disease in Type 2 Diabetes in Han Population in China. ( 28349069 )
2017
37
Atherosclerotic vascular diseases have really the same risk factors? Comparison between large abdominal aortic aneurysm and obstructive non-coronary arterial disease. ( 28509621 )
2017
38
Approach to concurrent coronary and carotid artery disease: Epidemiology, screening and treatment. ( 29451667 )
2017
39
Myeloperoxidase polymorphism and coronary artery disease risk: A meta-analysis. ( 28682877 )
2017
40
Assessment of coronary artery disease based on coronary flow velocity reserve by transthoracic Doppler echocardiography and coronary computed tomography angiography in a patient with dextrocardia: a case report. ( 29247297 )
2017
41
Expression of miR-23a induces telomere shortening and is associated with poor clinical outcomes in patients with coronary artery disease. ( 28646123 )
2017
42
Cigarette smoking represses expression of cytokine IL-12 and its regulator miR-21-An observational study in patients with coronary artery disease. ( 27765464 )
2017
43
Impact of nutritional assessment and body mass index on cardiovascular outcomes in patients with stable coronary artery disease. ( 28077227 )
2017
44
Hidradenitis Suppurativa is Associated with Myocardial Infarction, but Not Stroke or Peripheral Arterial Disease of Lower Extremities. ( 28914960 )
2017
45
Targeted Disruption of JCAD (Junctional Protein Associated With Coronary Artery Disease)/KIAA1462, a Coronary Artery Disease-Associated Gene Product, Inhibits Angiogenic Processes In Vitro and In Vivo. ( 28705794 )
2017
46
The efficacy of transcutaneous electrical nerve stimulation on the improvement of walking distance in patients with peripheral arterial disease with intermittent claudication: study protocol for a randomised controlled trial: the TENS-PAD study. ( 28797281 )
2017
47
Acquired coronary artery disease in adult patients with congenital heart disease: a true or a false problem? ( 28072626 )
2017
48
Serum Monokine Induced by Gamma Interferon Is Associated With Severity of Coronary Artery Disease. ( 28100872 )
2017
49
Update on diagnostics and treatment modalities for obstructive iliac artery disease. ( 28933524 )
2017
50
Concomitant Surgical Treatment of Symptomatic Carotid Artery Disease With a Coexisting Shamblin I Carotid Body Tumor. ( 28118794 )
2017

Variations for Arteries, Anomalies of

Expression for Arteries, Anomalies of

Search GEO for disease gene expression data for Arteries, Anomalies of.

Pathways for Arteries, Anomalies of

Pathways related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.2 AGTR1 ALB APOA1 APOB APOE COG2
2
Show member pathways
12.46 ALB APOA1 APOB APOE LPA
3 11.92 ALB IL6 INS TNNI3
4 11.88 ALB APOA1 APOE TNNI3
5
Show member pathways
11.81 APOA1 APOB APOE LPA
6
Show member pathways
11.72 ALB APOA1 APOB APOE
7 11.67 EDN1 IL6 INS NOS3
8 11.62 AGTR1 EDN1 IL6 NOS3
9
Show member pathways
11.61 ALB APOA1 APOB APOE CRP IL6
10 11.53 ACE AGTR1 REN
11
Show member pathways
11.36 ACE AGTR1 NOS3 REN
12 11.33 ALB APOA1 INS
13 11.18 APOA1 IL6 TLR9
14 11.03 APOB IL6 LPA PLAT PLG
15 10.79 ACE PLAT PLG
16 10.67 PLAT PLG

GO Terms for Arteries, Anomalies of

Cellular components related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 ACE ALB APOA1 APOB APOE CRP
2 blood microparticle GO:0072562 9.78 ALB APOA1 APOE PLG
3 endoplasmic reticulum lumen GO:0005788 9.73 ALB APOA1 APOB APOE IL6 INS
4 very-low-density lipoprotein particle GO:0034361 9.61 APOA1 APOB APOE
5 endocytic vesicle lumen GO:0071682 9.58 APOA1 APOB APOE
6 low-density lipoprotein particle GO:0034362 9.54 APOA1 APOB APOE
7 chylomicron GO:0042627 9.5 APOA1 APOB APOE
8 discoidal high-density lipoprotein particle GO:0034365 9.46 APOA1 APOE
9 extracellular space GO:0005615 9.44 ACE ALB APOA1 APOB APOE CRP
10 intermediate-density lipoprotein particle GO:0034363 9.33 APOA1 APOB APOE

Biological processes related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.98 ALB APOA1 APOB APOE IL6
2 receptor-mediated endocytosis GO:0006898 9.95 ALB APOA1 APOB APOE
3 cholesterol metabolic process GO:0008203 9.86 APOA1 APOB APOE
4 lipid transport GO:0006869 9.84 APOA1 APOB APOE LPA
5 cholesterol homeostasis GO:0042632 9.83 APOA1 APOB APOE
6 retinoid metabolic process GO:0001523 9.81 APOA1 APOB APOE
7 positive regulation of nitric oxide biosynthetic process GO:0045429 9.75 EDN1 INS TRPV1
8 regulation of blood pressure GO:0008217 9.71 ACE EDN1 NOS3 REN
9 acute-phase response GO:0006953 9.7 CRP IL6 INS
10 high-density lipoprotein particle assembly GO:0034380 9.69 APOA1 APOE
11 fatty acid homeostasis GO:0055089 9.69 APOE INS
12 triglyceride catabolic process GO:0019433 9.69 APOA1 APOB APOE
13 phospholipid efflux GO:0033700 9.68 APOA1 APOE
14 positive regulation of lipid biosynthetic process GO:0046889 9.68 APOE INS
15 angiotensin maturation GO:0002003 9.68 ACE REN
16 negative regulation of blood vessel diameter GO:0097756 9.67 CRP INS
17 neutrophil mediated immunity GO:0002446 9.67 ACE IL6
18 negative regulation of lipid storage GO:0010888 9.67 CRP IL6
19 lipoprotein metabolic process GO:0042157 9.67 APOA1 APOB APOE
20 negative regulation of platelet activation GO:0010544 9.66 APOE NOS3
21 high-density lipoprotein particle clearance GO:0034384 9.66 APOA1 APOE
22 cholesterol efflux GO:0033344 9.65 APOA1 APOB APOE
23 chylomicron remnant clearance GO:0034382 9.64 APOB APOE
24 neuron projection regeneration GO:0031102 9.64 APOA1 APOE
25 regulation of Cdc42 protein signal transduction GO:0032489 9.63 APOA1 APOE
26 regulation of vasoconstriction GO:0019229 9.63 ACE AGTR1 EDN1
27 negative regulation of hydrolase activity GO:0051346 9.62 APOA1 NOS3
28 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.61 EDN1 NOS3
29 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.61 ACE AGTR1
30 high-density lipoprotein particle remodeling GO:0034375 9.61 ALB APOA1 APOE
31 negative regulation of cellular protein metabolic process GO:0032269 9.6 APOE EDN1
32 very-low-density lipoprotein particle clearance GO:0034447 9.59 APOB APOE
33 renin-angiotensin regulation of aldosterone production GO:0002018 9.57 AGTR1 REN
34 positive regulation of dendritic spine maintenance GO:1902952 9.56 APOE INS
35 lipoprotein catabolic process GO:0042159 9.55 APOB APOE
36 chylomicron assembly GO:0034378 9.54 APOA1 APOB APOE
37 positive regulation of cholesterol esterification GO:0010873 9.5 AGTR1 APOA1 APOE
38 chylomicron remodeling GO:0034371 9.43 APOA1 APOB APOE
39 lipoprotein biosynthetic process GO:0042158 9.33 APOA1 APOB APOE
40 low-density lipoprotein particle remodeling GO:0034374 9.26 AGTR1 APOB APOE LPA
41 cellular protein metabolic process GO:0044267 9.17 ALB APOA1 APOB APOE IL6 INS
42 proteolysis GO:0006508 10.12 ACE ENSG00000264813 LPA PLAT PLG REN
43 lipid metabolic process GO:0006629 10.09 APOA1 APOB APOE LPA TRPV1
44 positive regulation of gene expression GO:0010628 10.02 APOB CRP IL6 INS TLR9

Molecular functions related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.8 ACE ENSG00000264813 LPA PLAT PLG REN
2 endopeptidase activity GO:0004175 9.63 ACE PLG REN
3 lipoprotein particle binding GO:0071813 9.43 APOA1 APOE
4 lipid transporter activity GO:0005319 9.43 APOA1 APOB APOE
5 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.4 APOA1 APOE
6 peptidyl-dipeptidase activity GO:0008241 9.37 ACE ENSG00000264813
7 bradykinin receptor binding GO:0031711 9.16 ACE AGTR1
8 low-density lipoprotein particle receptor binding GO:0050750 9.13 APOB APOE CRP
9 cholesterol transporter activity GO:0017127 8.8 APOA1 APOB APOE

Sources for Arteries, Anomalies of

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....